Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Coya Therapeutics, Inc. (COYA – Research Report), with a price target of $18.00.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Ram Selvaraju has given his Buy rating due to a combination of factors including the promising development milestones and upcoming catalysts for Coya Therapeutics, Inc. The company is preparing for significant data submissions and intellectual property filings related to their COYA 301/GLP-1 combination, which are expected to bolster their position in the market. Additionally, the anticipated start of the COYA-302 Phase 2 trial in ALS patients, upon IND acceptance, could lead to substantial milestone payments from their strategic partner, Dr. Reddy’s Laboratories.
Moreover, Coya Therapeutics is making strides in their research, with positive interim results from a study involving low-dose IL-2 and CTLA4-Ig in patients with frontotemporal dementia. The study showed improvements in Treg numbers and suppressive function, indicating potential therapeutic benefits. The company’s progress in their Treg-derived exosome program and the alignment with the FDA for a Phase 2b trial in ALS further support the Buy rating, highlighting the potential for Coya Therapeutics to address unmet medical needs in neurodegenerative diseases.
In another report released on May 13, BTIG also maintained a Buy rating on the stock with a $15.00 price target.